Though we were celebrating our 20th anniversary, 2017 still brought us many firsts. From building out our supply chain capabilities and becoming a licensed wholesaler, to maintaining drug inventories and visiting more than 50 partner sites, we wrote a new script for ourselves at every turn. Driven by the unmet needs of people facing cancer around the world, we implemented an organizational transformation that will allow us to better serve the patients we support and, one day, scale our treatment access model across every type of cancer.
For much of our history, we’ve managed patient access programs in partnership with pharma companies. In fact, we first began our treatment access work by co- developing a drug delivery model with Novartis – the Glivec® International Patient Assistance Program (GIPAP) – back in 2001. GIPAP, and programs like it, allowed us a unique opportunity to help patients. Yet, throughout the GIPAP years, we dreamed that one day we would be able to provide access for our patients to any medicine they needed, beyond Glivec®.
Today, this dream has come true. In 2017, moving away from the drug-centric approach, we implemented a new model that would be truly patient-centric: Max Access Solutions. In our new model, we have a way to offer multiple therapies to the same patient as prescribed by their doctor – and a way for any company that is willing to help to join in our mission.
We now offer a portfolio of eight, innovative, high-quality medicines to cancer patients in low- and middle-income countries through a collaborative mechanism I call our Humanitarian Partnership for Access to Cancer Treatment (PACT); and for those patients living with chronic myeloid leukemia (CML), we are able to channel any treatment otherwise only available in high-income countries.
This Humanitarian PACT has already been a dream come true. Now we have a new dream. Our dream is a world where every manufacturer of cancer treatment is part of our PACT, and together we ensure that, to the extent that patients can safely be treated in countries with no other form of local access, we activate the Max Access Solution so no patient goes without medicine.
I am so proud of all we’ve accomplished in 2017 – and in our first 20 years as an organization. As you read our annual report, I hope you are too. We couldn’t have done it without you. Thank you for your continued support as we turn the page to our next 20 years.
CEO of The Max Foundation
Focused specifically on low- and middle-income countries, Max Access Solutions allows us to deliver targeted cancer treatments to patients who would have no other way to access them. Thanks to a proprietary, real-time, patient-tracking tool and our global system of collaborations, we’re able to deliver the right treatment to the right patient in the right dose at the right time.
In 2017, our first full year turning the page to Max Access Solutions, we successfully delivered 713,695 daily doses of cancer medication to 11,017 patients in 66 countries. In the years to come, we aim to complete the transition and move all the patients we currently support into this new model.
A patient-centered model means we can offer multiple treatment options for the same disease. So when Alassane – a husband and father from Senegal – needed to change medications, he was able to get a second-line treatment through Max Access Solutions.
In 2017, our longtime partnership with Novartis was reimagined as a best practice collaboration called CMLPath to Care™. Implemented under the umbrella of Max Access Solutions, the contribution of CMLPath to Care™ is enormous. Of the 700,000+ daily doses we distributed in our first year, 91% were Novartis’ transformative treatment, Glivec®.
From there, a complex system is activated: donated medicines leave the manufacturing plant, get routed through our validated supply chain, to our partner institutions, and into the patient’s hand. Though we only launched Max Access Solutions in January of 2017, by the end of the calendar year we had added more than 220 doctors around the globe to our network.
We’re proud to be affiliated with so many dedicated doctors and healthcare providers. They form the front line in bringing dignity and hope to people facing cancer. Without them, we could never achieve our mission. We look forward to adding more ways to support these key partners as our transition to Max Access Solutions continues.
Meet Dr. Khamida Kazakbaeva. Lovingly known as the “Mother Teresa of Uzbekistan” among those she supports, she has dedicated her life to her patients.
She is the only trained hematologist in her region, so many of her patients must travel hundreds of miles to see her for checkups and refilling medications. To lessen the burden on them, Dr. Kazakbaeva created a biannual fundraiser called “Closer to Patients, Closer to Max.” She uses the money raised to fund her travel to four strategic areas around the country, setting up a mobile clinic in each where local patients can visit her nearby, rather than making the days-long journey to Tashkent.
We at The Max Foundation are humbled by Dr. Kazakbaeva’s dedication and honored to help her bring dignity and hope to people facing cancer in Uzbekistan.
“I had the honor of meeting Dr. Kazakbaeva in Uzbekistan and accompanied her on several home visits to treat patients and deliver their medicine. It was so humbling to see the strong relationships she has built with each one. Like all the physicians in our network, Dr. Kazakbaeva serves as an inspiration to do all we can for patients.”
Erin Lindsay Schneider, Senior Program Manager, USA
Having multiple partners allows us to offer multiple targeted therapies – empowering doctors and patients to make choices about treatment. And, as our drug portfolio has grown, so have the disease areas in which we work.
When we first launched The Max Foundation 20 years ago, our focus was on rare blood cancers. Today, we also offer therapies for gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), and non-small cell lung cancer. Our next goal is to continue to expand the portfolio of medications available in every country in which we work.
Five multinational pharmaceutical companies have joined with us to forge a Humanitarian Partnership for Access to Cancer Treatment (PACT) – a commitment to providing cancer medicine to patients in low- and middle-income countries who would have no other means of access. Each company within the PACT has committed to providing access for a different number of patients within their capabilities, but all have committed their support for as long as each patient needs it.
With Tanner’s help – and in Max Access Solution’s inaugural year – we successfully delivered 147 shipments of targeted cancer medications to doctors and clinics the world over; monitoring their safety and quality from end-to-end along our validated supply chain.
And, we overcame some major barriers along the way: an earthquake, a volcanic eruption, and a political revolution; yet we endured and successfully delivered the needed medication to our patients.
“Without The Max Foundation’s effort in bringing the treatment access program to our hospital, patients in East Malaysia would have to travel to the capital of our country (only by air) to receive treatment for their cancer. This is an impossible journey for many to make on a regular basis, which would leave them with no access to treatment at all! Thanks to you, they have the care they need, but also, they have hope.”
Dr. Lu Chee Men, Queen Elizabeth II Hospital, Malaysia
In 2017, we established a validated supply chain into 98 cancer-treating institutions around the world.
Republican Haematology Centre · Armenia
Inst. of the Rep. of Azerbaijan on Tranfusiology and Hematology · Azerbaijan
Hematology Oncology Consultants · Bahamas
Belorussian Hematology and Bone Marrow Transplant · Belarus
Centre National Hospitalier Universitaire Hubert K. MAGA · Benin
Jigme Dorji Wangchuck National Referral Hospital · Bhutan
Clínica Los Olivos · Bolivia
Diagnosis Instituto de Medicina · Bolivia
Hospital de Clínicas Universitario · Bolivia
Hospital Universitario Santa Bárbara · Bolivia
Instituto Boliviano de Oncohematología · Bolivia
Instituto Oncologico del Oriente Boliviano · Bolivia
Centro de Hematologia e Hemoterapia – U. Estadual de Campinas · Brazil
Hospital das Clinicas das UFG · Brazil
Centre Hospitalier Universitaire Yalgado Ouedraogo · Burkina Faso
Mercy Medical Center · Cambodia
Hospital General Yaoundé · Cameroon
CHU de Yopougon · Cote d’Ivoire
Centre Hospitalier Monkole · Democratic Republic of Congo
Bairo Pite Clinic Lanud · East Timor
North Estonia Medical Center · Estonia
Tikur Anbessa (Black Lion) Hospital · Ethiopia
Colonial War Memorial Hospital · Fiji
Institut de Cancerologie Angondje · Gabon
Hematology and Chemotherapy Clinic “HEMA” · Georgia
Tbilisi Gov. Inst. of Hematology and Transfusion · Georgia
Komfo Anokye Teaching Hospital · Ghana
Korle-Bu Teaching Hospital · Ghana
Zanmi Lasante · Haiti
Centro de Cancer Emma R. De Callejas · Honduras
Apollo Speciality Hospital (Delhi) · India
Rajiv Gandhi Cancer Institute & Research Ctr. · India
Sir Ganga Ram Hospital · India
VPS Lakeshore Hospital · India
Cornwall Regional Hospital · Jamaica
Kingston Public Hospital · Jamaica
University Hospital Of The West Indies · Jamaica
Regional Hospital · Kazakhstan
Scientific Center of Pediatrics and Pediatrics Surgery · Kazakhstan
The Nairobi Hospital · Kenya
The National Centre of Oncology · Kyrgyzstan
Oncology and Transfusion Medicine Centre Vilnius University · Lithuania
Service d’Oncologie C.H.U – H.J.R.A · Madagascar
College of Medicine & Queen Elizabeth Central Hospital · Malawi
Hospital Ampang · Malaysia
Hospital Miri · Malaysia
Hospital Pulau Pinang · Malaysia
Hospital Queen Elizabeth · Malaysia
Hospital Raja Permaisuri Bainun · Malaysia
Hospital Sibu · Malaysia
Hospital Sultanah Aminah · Malaysia
Hospital Tengku Ampuan Afzan · Malaysia
Hospital Umum Sarawak · Malaysia
Subang Jaya Medical Centre · Malaysia
Service d’Hématologie Oncologie Médicale · Mali
Victoria Hospital Candos · Mauritius
Hosp. Central de San Luis Potosí “Dr. Morones Prieto” · Mexico
Hosp. Chiapas nos Une “Dr. Gómez Maza” · Mexico
Hospital General de Mexico · Mexico
Hospital General de Occidente, Secretaria de Salud · Mexico
Hosp. U. de Nuevo León “Dr. José Eleuterio González” · Mexico
Instituto Nacional de Cancerologia (INCAN) · Mexico
Inst. Nacional de Ciencias Médicas y Nutrición · Mexico
Unidad de Hematología y Transfusión · Mexico
Institute of Oncology · Moldova
First Central Hospital · Mongolia
B.P. Koirala Memorial Hospital · Nepal
Patan Hospital · Nepal
Hospital Roberto Calderon Gutierrez · Nicaragua
Hôpital National de Niamey · Niger
Obafemi Awolowo University Teaching Hospital · Nigeria
University of Nigeria Teaching Hospital · Nigeria
Nazarene Hospital · Papua New Guinea
Hospital de Clínicas · Paraguay
Philippine General Hospital · Philippines
Univ. of Santo Tomas Hospital · Philippines
Centre Hospitalier et Univ. de Brazzaville · Republic of Congo
Rwanda Military Hospital · Rwanda
Rwinkwavu District Hospital · Rwanda
Victoria Hospital · Saint Lucia
Hospital Dalal Jamm · Senegal
Seychelles Hospital · Seychelles
Connaught Teaching Hospital · Sierra Leone
National Referral Hospital · Solomon Islands
The Radiation and Isotope Centre · Sudan
University Hospital Paramaribo · Suriname
National Medical Center · Tajikistan
Kilimanjaro Christian Medical Center · Tanzania
Ocean Road Cancer Institute · Tanzania
Ramithibodi Hospital · Thailand
Siriraj Hospital · Thailand
Campus Teaching Hospital of Lome · Togo
Joint Clinical Research Center · Uganda
Mulago Hosp. Uganda Cancer Institute · Uganda
Inst. of Blood Pathology and Transfusion Med. · Ukraine
Scientific Research Inst. for Hem. and Blood Transfusion · Uzbekistan
University Teaching Hospital · Zambia
Parirenyatwa Hospital · Zimbabwe
The Max Foundation developed its own real-time program management tool – Patient Access Tracking System (PATS®) – that can be used simultaneously by our own program team and by treating physicians at partner institutions. Creating this sophisticated tool that can operate in low-resource settings has put The Max Foundation ahead of the curve in providing a complete, end-to-end access solution. PATS® is able to support the program on one end improving patients’ ability to comply with treatment, while on the other end supporting the implementation of successful planning and forecasting models.
For people living with cancer, finding a balance between daily cancer care and living without worry is vital. Our Day by Day support program is implemented through regular phone calls, distribution of informational materials and, in specific cases, patient support meetings and disease workshops hosted by our local representative in the patient’s country. Knowing that some kinds of cancer have become chronic conditions, attending to both the short- and long-term needs of patients and families is critical.
One of the biggest barriers to cancer treatment access in low- and middle-income countries is the shortage of molecular diagnostic tools such as polymerase chain reaction (PCR) testing. In addition to its diagnostic function, PCR testing is also the best way to monitor a patient’s ongoing response to treatment, but many countries lack access to – or even awareness of – these critical tools. So we’ve started several initiatives to help close the gaps:
In 2017, we developed an advocacy toolkit for leaders of patient associations and provided 27 grants to patient associations for PCR awareness activities – all through My PCR (mypcr.org).
Through a preferential pricing agreement with Cepheid, we channeled
250 test kits to hospitals and clinics, providing diagnostic access to 2,500 patients in 2017.
Through a diagnostic partnership with the Fred Hutchinson Cancer Research Center, we made it possible for 61 patients to access free testing using dried blood samples on paper cards – a method pioneered by the Radich Lab.
“Twice a month I travel many hours by bus from Santo Domingo, to Santiago, accompany patients to get their blood samples, and bring the samples back to Santo Domingo so they can be PCR tested at Hospital Heriberto Pieter, where the GeneXpert machine is located.”
Nilexis Bernard Rodríguez
Program Coordinator, Dominican Republic
The planned transition of the GIPAP program to CMLPath to Care™ under the umbrella of the Max Access Solutions model, launched in July of 2017, required the organization to stock up its inventory to ensure a continuous supply of medicines to patients in the program.
While 50 out of the 67 countries to be transitioned did so in 2017, at year end, the organization was holding a substantial volume of inventory on hand while we sought import permits and other necessary regulatory documentation for distribution at the different sites.
|Gifts-In-Kind · Pharmaceuticals||190,595,434||96.6%|
|Corporate Services Agreements||1,070,985||0.5%|
|Contributions, Grants & Sponsorships||5,386,877||2.7%|
|Diagnostic Program Revenue||312,689||0.2%|
|Program Services Expense||54,727,479||97.8%|
|Management & General||742,814||1.3%|
Patricia Pearce, Chief Financial Officer Consultant
Prior to 2017, The Max Foundation’s fair value of donated pharmaceuticals was based on prices from Thomas Reuters Red Book Average Wholesale Price (AWP). During 2017, The Max Foundation obtained fair value data from a third-party source which reflects wholesale prices available in multiple relevant international markets. The gifts-in-kind are recorded, by drug, based on the estimated fair value in the relevant international market of highest volume. During 2017, The Max Foundation modified its agreements with several pharmaceutical companies. Pharmaceutical gifts-in-kind are now donated to The Max Foundation for use in its programs, whereas in prior years the pharmaceuticals were provided directly by the companies to the end users. As a result, the volume and total value of gifts-in-kind recognized in the consolidated financial statements is significantly higher in 2017.
We offer our heartfelt thanks to our partners and friends for sharing in our mission.
Andrew W. Lyon Travel
Beresford Booth, PLLC
Bourne Capital Partners, LLC
Choice Organic Teas
Davis Wright Tremaine LLP
Expertasia Marketing Consulting & Services Co.
Fred Hutchinson Cancer Research Center
Global Fiberglass Solutions, Inc.
Greenwood Masonic Lodge
La Minutera Seafood Restaurant
Latin America Leukemia Net
Rainier Masonic Lodge
Tanner Pharma Group
The Woodshed Gallery
UNITS Moving & Portable Storage Seattle & Bellevue
Your support allows us to extend the reach of our programs and expand the services we offer to people facing cancer. Every dollar given, hat knitted, event hosted, and story shared brings a patient closer to accessing treatment – and access to treatment is access to life. To honor those who have been so generous and faithful in their support, here’s a look back at some of the ways our community supported patients in 2017.
Priyanka Kandalgaokar, Program Officer, India
The Max Global Experience is a new fundraising and engagement event in which supporters travel together with us to gain a better under- standing of our work, meet patient leaders, and share in an unforgettable adventure. In 2017, 23 participants traveled to Malaysia to climb Mount Kinabalu with local cancer survivor and patient advocate, Tony Leo. Leading up to the event, participants tapped into their personal networks,introducing us to supporters who donated more than $105,000 toward education, awareness, and treatment access.
With Love in Every Stitch is a program inviting our community to donate hand-knit hats for children facing cancer. We received 374 handmade items in 2017 and sent them to patient organizations to give out in hospitals in Mexico, Chile, Mongolia, and Ethiopia – all thanks to the tireless work of our knitters.
Our 20th Anniversary Celebration was held in Seattle, Washington, on Max’s Day – October 19th. Nearly 200 friends, partners, and guests from around the world joined us for a night of festivities and reflection. Staffed by community volunteers, the event brought in $100,000 in sponsorships and donations – and the first $20,000 was matched by a generous supporter.
Tony Leo, Patient Leader, Malaysia
We are grateful to all the new friends we made in 2017, and the old friends who have been by our side for years. We thank you all for sharing in our daily mission and our nightly dream – creating a world in which all people face cancer with dignity and hope. Your ongoing support has a direct impact on patients and their families. By giving them access to cancer treatment, you are giving them the gift of time with loved ones.
Paula Boultbee · President of the Board · Principal at PTB Consulting LLC
Jerry Scott, CPA · Treasurer of the Board · Chartered Global Management Accountant
David Tingstad · Secretary of the Board · Beresford Booth PLLC Law
Pat Garcia-Gonzalez · Chief Executive Officer & Founder
Robert Farmer · Board Member · CML Survivor & Photographer
Tracey Higgins · Board Member · Edmonds Community College
Grant Rubenstein · Board Member · Rosen~Harbottle Commercial Real Estate
Michele Baccarani, MD
Jorge E. Cortes, MD
Brian J. Druker, MD
Francois Guilhot, MD
Andreas Hochhaus, MD
Timothy Hughes, MD
Michael J. Mauro, MD
Javier Pinillia-Ibarz, MD
Delphine Rea, MD
Neil P. Shah, MD
Moshe Talpaz, MD
Matía Chacón, MD
George D. Demetri, MD
Peter Reichardt, MD
Jonathan Trent, MD
Carolyn Blasdel, FNP-BC
R. Banks Bourne, MBA
Gilberto de Lima Lopes, Jr., MD
Michele Galen, J.D.
Teresa Guillien, MPA
William E. Heisel
Michael Mandola, PhD
Jerald Radich, MD
Carlos Rodriguez-Galindo, MD
Lawrence N. Shulman, MD
Andy Stergachis, PhD
Pat Garcia-Gonzalez, Chief Executive Officer
Erin Schwartz, VP of Global Engagement
Inés García González, Region Head Latin America
Mei Ching Ong, Region Head Asia Pacific
Danielle Matia, Region Head Africa & Middle East
Viji Venkatesh, Region Head South Asia
Ann Kim Novakowski, Associate Program Director
J. Michael Wrigglesworth, Director of Global IT Solutions
Seattle, Washington, USA
Craig Anderson, Director of IT
Josué Blanco, Senior Brand Manager
Barbara Carpenter, Executive Assistant
Courtney Czarnecki, Administrative Assistant
Lorie Gail, Consulting Controller
Paula Lacy, Administrative Assistant
Scott Lutz, Accountant Assistant
Meg Mager, Senior Program Manager
Patricia Pearce, CFO Consultant
Kristina Pfeil, Human Resources Consultant
Winona Rennick, Development Manager
Erin Lindsay Schneider, Senior Program Manager
Scott Shearer, Quality Assurance Consultant
Huey Yeh, Controller
Mercedes Arteaga, Regional Program Officer
Maria Victoria Duhalde, Local Program Coordinator
Melisa Fazio, Local Program Coordinator
Lyat Granati, Local Program Coordinator
Martha Rosario Molina, Local Program Coordinator
Nilexis Bernard Rodríguez, Local Program Coordinator
Tenaye A. Ashebir, Local Program Coordinator
Evelyn Berduo, Local Program Coordinator
Ankita Borkar, Administrative Executive
Phillip Fernandes, Administrative Assistant
Santosh Kadam, Accounts/Office Manager
Priyanka Kandalgaokar, Program Officer
Prasad Kothekar, Administrative Executive
Sherly Kochi, Volunteer
Azim Mohd, Driver
Ashika Naik, Local Program Coordinator
Beena Narayanan, Program Officer
Jyotiy Parameshwaran, Local Program Coordinator
Sudha Samineni, Program Officer
Shalini Subramanian, Local Program Coordinator
Vijaya Sundaram, Program Officer
Ameya Surve, Program Officer
Komal Surve, Local Program Coordinator
Vidya Tahilramani, Local Program Coordinator
Anshika Tandon, Local Program Coordinator
Julie Soundarva, Housekeeping Staff
Lucy Mwangi, Local Program Coordinator
Ghai Yein Lee, Local Program Coordinator
Nor Aina Binti Abd Rahim, Administrative Executive
Yee Jia Heng, Program Officer
Shirleen Low, Program Officer
Cynthia Figueroa Guerra, Program Officer
Mariana Rubi Gonzalez, Local Program Coordinator
Adetokunbo M. Bello, Local Program Coordinator
Sweta Agrawal, Local Program Coordinator
Nelia Media, Program Officer
Mame Fall, Local Program Coordinator
Geraldine Botha, Local Program Coordinator
Catherina Scheepers, Regional Program Officer
Krittapart Artharn, Local Program Coordinator
Thaned Kairaj, Local Program Coordinator
Wirat Sae-Kuai, Program Officer
Piyapong Siriviriyanum, Program Officer
Sukrob Saliev, Local Program Coordinator
Tang Thi Thanh Thao, Local Program Coordinator
What started as a small patient gathering in a hospital in Manila, has evolved into a global network of 77 independent patient associations in 57 countries whose efforts are central to our wraparound support.
Asociación de Leucemia Mieloide Argentina · Argentina
CML Patient Association Armenia · Armenia
Bangladesh CML Supporting Group · Bangladesh
Celebrando la Vida · Bolivia
Fundación Esperanza Nueva Bolivia
ABRALE · Brazil
Groupe d’Appui aux Survivants du Cancer · Burkina Faso
Max Miracle · Cambodia
AMACAS · Cameroon
Corporación Nacional Maxi Vida Chile · Chile
Shanghai Roots and Shoots · China
Fundación Colombiana de Leucemia y Linfoma · Colombia
Fundación Esperanza Viva · Colombia
Agalemo · Costa Rica
Un Paso Max · Dominican Republic
Esperanza y Vida · Ecuador
CanSurvive · Egypt
Asociación Amor a la Vida · El Salvador
Mathiwos Wondu-YeEthiopia Cancer Society · Ethiopia
CML Patients’ Foundation of Ethiopia · Ethiopia
The Alliance of CML Patients of Georgia · Georgia
Chronic Myeloid Leukemia Advocates of Ghana · Ghana
Asociación de Pacientes con Leucemia Mieloide Crónica · Guatemala
Asociación Hondureña de Lucha contra el Cáncer · Honduras
Friends of Max · India
ELGEKA West Java · Indonesia
YKI Jakarta · Indonesia
Israel CML Patients Organization · Israel
IZUMI · Japan
Association of Patients with Hemoblastoses · Kazakhstan
Childhood Cancer Initiative · Kenya
Henzo Kenya · Kenya
Nakuru Hospice · Kenya
Association Fanomezana LMC · Madagascar
Max Family Society Malaysia · Malaysia
Association Leucémie, espoir Mali · Mali
Alianza Anticáncer Infantil, A.B.P. · Mexico
Asociación Mexicana de Leucemia y GIST · Mexico
Grupo Unido de Leucemia A.C. · Mexico
Manitas la Pulsera de Leucemia · Mexico
Luz de Vida · Mexico
National Cancer Council Mongolia · Mongolia
Association des Malades Atteints de Leucémies · Morocco
Blood Cancer Society Nepal Nepal
Children Cancer Foundation Nepal · Nepal
Fundación Alas de Vida · Nicaragua
Association de Lutte Contre la Leucémie · Niger
MaxCare Nigeria · Nigeria
KIRAN · Pakistan
Patient’s Friends Society-Jerusalem · Palestine
Fundación Unidos contra el Cáncer · Paraguay
Esperantra · Peru
Luz de Esperanza · Peru
Touched By Max · Philippines
Polish Association for CML Patients Aid · Poland
Associação Portuguesa contra a Leucemia · Portugal
A.G.I.L du Sénégal · Senegal
CML Association of Serbia · Serbia
Crusaders Club Ministry · Sierra Leone
Children’s Cancer Foundation Singapore
Slovenian Lymphoma & Leukemia Patient Association Slovenia
Childhood Cancer Foundation South Africa · South Africa
CMLSA · South Africa
People Living with Cancer South Africa
Korea Blood Cancer Association · South Korea
Zero Club CML · South Korea
Taiwan Bone Marrow Transplantation AssociationTaiwan
Tanzania CML Patient Group Tanzania
MaxSmiles · Thailand
NGO APSBES/DILIGENCE GROUP · Togo
Emirates Association for Cancer Support · UAE
Leukemia & GIST Advocacy Fraternity of Uganda · Uganda
Osanna · Ukraine
Uzbekistan CML Patients League · Uzbekistan
Asociación de Ayuda a Pacientes Hemato-oncológicos Venezuela
Max’s Vie · Vietnam
CML Zimbabwe · Zimbabawe
Today, we go beyond linking people to existing resources and, instead, create new ones ourselves. We’ve co-developed the most successful oncological patient access program in history, forged a Humanitarian PACT with five multinational pharmaceutical companies, and just this year, launched a new patient-centered model that could redefine the approach to cancer treatment access in our field.
It feels like nothing short of a dream. And it all started with a brave young boy named Max.
Maximiliano “Max” Rivarola was from Argentina, but he and his family had to travel across the globe to get treatment for his leukemia. Though he was given the best possible care in the United States, the therapies available at the time were not enough to save him.
When Max’s family was faced with the end of his life, instead of giving up hope, they marked a new beginning. The family started The Max Foundation to ensure all people could access the very best care, no matter where they live.
Stay connected to the journey. Follow along on social media.